文献速递心脏核医学

双嘧达莫PET心肌灌注显像中脾脏反应比的预后价值

Prognostic utility of splenic response ratio in dipyridamole PET myocardial perfusion imaging.
PubMed 文献 · J Nucl Cardiol · 2018-04-12

研究连续纳入839例行双嘧达莫铷-82 PET心肌灌注显像的患者,测量脾脏与肝脏铷-82活性并计算脾脏反应比(SRR)。在负荷总评分与负荷差值评分均正常的患者中,脾脏无反应者1年主要不良心脏事件(MACE)发生率显著高于有反应者;在负荷差值评分正常者中,脾脏反应是MACE的独立预测因子(HR 2.97,95%CI 1.10~8.04,P=.033)。

要点

  • 839例筛查患者中703例(84%)显像可见脾脏,据此计算脾脏反应比。
  • 负荷总评分正常组:脾脏无反应者MACE 7.8% vs 有反应者2.9%(P=.027)。
  • 负荷差值评分正常者中脾脏反应为MACE独立预测因子(HR 2.97,95%CI 1.10~8.04,P=.033)。

主要发现

  • 839例筛查患者中703例(84%)显像可见脾脏。
  • 负荷总评分正常组中,脾脏无反应者MACE发生率为7.8%,脾脏有反应者为2.9%(P=.027)。
  • 负荷差值评分正常组中,脾脏无反应者MACE发生率为7.4%,脾脏有反应者为2.2%(P=.014)。
  • 在负荷差值评分正常患者的多因素分析中,脾脏反应是MACE的显著独立预测因子(HR 2.97,95%CI 1.10~8.04,P=.033)。

关键数值与推荐

  • 脾脏反应比(SRR)计算公式:SRR=(脾脏负荷/肝脏负荷)/(脾脏静息/肝脏静息)。
  • 在负荷差值评分正常患者中,脾脏反应预测MACE的HR为2.97(95%CI 1.10~8.04,P=.033)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiac magnetic resonance perfusion studies with adenosine stress have shown that splenic response can identify patients with inadequate pharmacologic stress. We investigate the incremental prognostic impact of splenic response ratio (SRR) in patients with normal Rubidium (Rb)-82 PET myocardial perfusion imaging (MPI). METHODS: Consecutive patients undergoing dipyridamole Rb-82 PET MPI for the evaluation of coronary artery disease were screened. Spleen and liver Rb-82 activity was measured and the SRR was calculated: SRR = (Spleen stress/Liver stress)/(Spleen rest/Liver rest). Major adverse cardiac events (MACE) were determined at 1 year of follow-up in patients with normal summed stress score and normal summed difference score. RESULTS: Of the 839 patients screened, the spleen was visualized in 703 (84%) of scans. There was significantly higher MACE observed in splenic non-responders vs splenic responders in both the normal SSS (7.8% vs 2.9%, P = .027) and the normal SDS groups (7.4% vs 2.2%, P = .014). In multivariate analysis in patients with normal SDS, splenic response was a significant, independent predictor of MACE (HR 2.97, 95% CI 1.10 to 8.04, P = .033). CONCLUSIONS: SRR is a novel imaging metric to identify patients with sub-maximal vasodilator stress and an incremental prognostic marker in patients with normal SDS and SSS (Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT01128023).

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Bami K, Tewari S, Guirguis F, et al. Prognostic utility of splenic response ratio in dipyridamole PET myocardial perfusion imaging. J Nucl Cardiol. 2018. PMID: 29651739. doi:10.1007/s12350-018-1269-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。